Fermex Limited 04966280 true 2023-01-01 2023-12-31 2023-12-31 The principal activity of the company is the supply and distribution of bakery ingredients until the 31 December 2016 when the trade and its associated assets and liabilities were hived up into Lesaffre UK and Ireland Limited (formerly DCL Yeast Limited), the company's immediate parent company at which time the company ceased trading. Digita Accounts Production Advanced 6.30.9574.0 true V P Saingier P-Y Couasnon 04966280 2023-01-01 2023-12-31 04966280 2023-12-31 04966280 bus:Director13 2023-12-31 04966280 bus:Director14 2023-12-31 04966280 core:ShareCapital 2023-12-31 04966280 core:CurrentFinancialInstruments 2023-12-31 04966280 bus:FRS102 2023-01-01 2023-12-31 04966280 bus:AuditExempt-NoAccountantsReport 2023-01-01 2023-12-31 04966280 bus:FullAccounts 2023-01-01 2023-12-31 04966280 bus:RegisteredOffice 2023-01-01 2023-12-31 04966280 bus:Director12 2023-01-01 2023-12-31 04966280 bus:Director13 2023-01-01 2023-12-31 04966280 bus:Director14 2023-01-01 2023-12-31 04966280 bus:EntityHasNeverTraded 2023-01-01 2023-12-31 04966280 bus:PrivateLimitedCompanyLtd 2023-01-01 2023-12-31 04966280 countries:AllCountries 2023-01-01 2023-12-31 04966280 2022-01-01 2022-12-31 04966280 2022-12-31 04966280 core:ShareCapital 2022-12-31 04966280 core:CurrentFinancialInstruments 2022-12-31 iso4217:GBP xbrli:pure

Registration number: 04966280


Fermex Limited

Annual Report and Unaudited Financial Statements

for the Year Ended 31 December 2023

 

Fermex Limited

Directors' Report for the Year Ended 31 December 2023

The directors present their report and the financial statements for the year ended 31 December 2023.

Directors of the company

The directors who held office during the year were as follows:

V P Saingier

M C Perchereau (ceased 28 August 2023)

P-Y Couasnon (appointed 5 September 2023)

Trading status
The company has not traded during the year.

Small companies provision statement

This report has been prepared in accordance with the small companies regime under the Companies Act 2006.

Approved and authorised by the Board on 29 February 2024 and signed on its behalf by:
 

.........................................
P-Y Couasnon
Director

 

Fermex Limited

Profit and Loss Account for the Year Ended 31 December 2023

The company has not traded during the year. During this year, the company received no income and incurred no expenditure and therefore made neither profit nor loss.

 

Fermex Limited

(Registration number: 04966280)
Balance Sheet as at 31 December 2023

Note

2023
£

2022
£

Current assets

 

Debtors

4

1

1

Capital and reserves

 

Called up share capital

1

1

Shareholders' funds

 

1

1

These financial statements have been prepared in accordance with the special provisions relating to companies subject to the small companies regime within Part 15 of the Companies Act 2006.

For the financial year ending 31 December 2023 the company was entitled to exemption from audit under section 480 of the Companies Act 2006 relating to dormant companies.

Directors' responsibilities:

The members have not required the company to obtain an audit of its accounts for the year in question in accordance with section 476; and

The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.

Approved and authorised by the Board on 29 February 2024 and signed on its behalf by:
 


P-Y Couasnon
Director

 

Fermex Limited

Notes to the Unaudited Financial Statements for the Year Ended 31 December 2023

1

General information

The company is a private company limited by share capital, incorporated in UK and registered in England and Wales.

The address of its registered office is:
E3 Blackpole (East)
Blackpole Road
Worcester
Worcestershire
WR3 8SG

2

Accounting policies

Summary of significant accounting policies and key accounting estimates

The principal accounting policies applied in the preparation of these financial statements are set out below. These policies have been consistently applied to all the years presented, unless otherwise stated.

Statement of compliance

These financial statements have been prepared in accordance with Financial Reporting Standard 102 Section 1A smaller entities - 'The Financial Reporting Standard applicable in the United Kingdom and Republic of Ireland' and the Companies Act 2006 (as applicable to companies subject to the small companies' regime).

Basis of preparation

These financial statements have been prepared using the historical cost convention except for, where disclosed in these accounting policies, certain items that are shown at fair value.

The presentational currency of the financial statements is Pound Sterling, being the functional currency of the primary economic environment in which the company operates. Monetary amounts in these financial statements are rounded to the nearest £.

Judgements

No significant judgements have been made by management in preparing these financial statements.

Key sources of estimation uncertainty

No key sources of estimation uncertainty have been identified by management in preparing these financial statements other than those detailed in these accounting policies.

Share capital

Ordinary shares are classified as equity. Equity instruments are measured at the fair value of the cash or other resources received or receivable, net of the direct costs of issuing the equity instruments. If payment is deferred and the time value of money is material, the initial measurement is on a present value basis.

 

Fermex Limited

Notes to the Unaudited Financial Statements for the Year Ended 31 December 2023

Financial instruments

Classification
Financial instruments are classified and accounted for according to the substance of the contractual arrangement, as financial assets, financial liabilities or equity instruments. An equity instrument is any contract that evidences a residual interest in the assets of the company after deducting all of its liabilities. Where shares are issued, any component that creates a financial liability of the company is presented as a liability on the balance sheet. The corresponding dividends relating to the liability component are charged as interest expenses in the profit and loss account.
 Recognition and measurement
All financial assets and liabilities are initially measured at transaction price (including transaction costs), except for those financial assets classified as at fair value through profit or loss, which are initially measured at fair value (which is normally the transaction price excluding transaction costs), unless the arrangement constitutes a financing transaction. If an arrangement constitutes a financing transaction, the financial asset or financial liability is measured at the present value of the future payments discounted at a market rate of interest for a similar debt instrument.
 Impairment
Assets, other than those measured at fair value, are assessed for indicators of impairment at each balance sheet date. If there is objective evidence of impairment, an impairment loss is recognised in profit or loss as described below.

A non financial asset is impaired where there is objective evidence that, as a result of one or more events that occurred after initial recognition, the estimated recoverable value of the asset has been reduced. The recoverable amount of an asset is the higher of its fair value less costs to sell and its value in use.

The recoverable amount of goodwill is derived from measurement of the present value of the future cash flows of the cash-generating units ('CGUs') of which the goodwill is a part. Any impairment loss in respect of a CGU is allocated first to the goodwill attached to that CGU, and then to other assets within that CGU on a pro-rata basis.

Where indicators exist for a decrease in impairment loss, the prior impairment loss is tested to determine reversal. An impairment loss is reversed on an individual impaired asset to the extent that the revised recoverable value does not lead to a revised carrying amount higher than the carrying value had no impairment been recognised. Where a reversal of impairment occurs in respect of a CGU, the reversal is applied first to the assets (other than goodwill) of the CGU on a pro-rata basis and then to any goodwill allocated to that CGU.

For financial assets carried at amortised cost, the amount of an impairment is the difference between the asset’s carrying amount and the present value of estimated future cash flows, discounted at the financial asset’s original effective interest rate.

For financial assets carried at cost less impairment, the impairment loss is the difference between the asset’s carrying amount and the best estimate of the amount that would be received for the asset if it were to be sold at the reporting date.

Where indicators exist for a decrease in impairment loss, and the decrease can be related objectively to an event occurring after the impairment was recognised, the prior impairment loss is tested to determine reversal. An impairment loss is reversed on an individual impaired financial asset to the extent that the revised recoverable value does not lead to a revised carrying amount higher than the carrying value had no impairment been recognised.

3

Staff numbers

The average number of persons employed by the company (including directors) during the year, was 2 (2022 - 2).

4

Debtors

2023
£

2022
£

Amounts owed by related parties

1

1

1

1